Acifran: A Selective HM74A/GPR109A and GPR109B Agonist for Lipid Metabolism Regulation

Executive Summary: Acifran ((R)-5-methyl-4-oxo-5-phenyl-4,5-dihydrofuran-2-carboxylic acid) is a potent, selective agonist for the HM74A/GPR109A and GPR109B receptors, also known as hydroxycarboxylic acid receptors (HCAR2 and HCAR3) (Ye et al., 2025). Acifran’s atomic interactions and selectivity were mapped via high-resolution cryo-EM, providing mechanistic clarity for lipid signaling pathway studies. Its robust activity profile (≥98% purity) and chemical stability make it indispensable for research on lipid metabolism and metabolic disorders (APExBIO product page). Benchmarking experiments reveal reproducibility and specific receptor targeting, making Acifran a reference compound for both mechanistic and translational research. Researchers are advised to use freshly prepared solutions and adhere to -20°C storage for optimal results.

Biological Rationale

Lipid metabolism is central to energy balance and cellular signaling. Disruption in lipid signaling contributes to metabolic disorders, including dyslipidemia and type 2 diabetes (Ye et al., 2025). The hydroxycarboxylic acid receptors HCAR2 (HM74A/GPR109A) and HCAR3 (GPR109B) are G-protein coupled receptors (GPCRs) that sense endogenous metabolites and regulate lipid mobilization. Selective modulation of these receptors enables targeted investigation of lipid signaling mechanisms. Acifran, by acting as a selective agonist at both HM74A/GPR109A and GPR109B, facilitates controlled studies of these pathways, distinguishing receptor-specific effects. This strategic targeting is crucial for dissecting the roles of HCAR2 and HCAR3 in metabolic syndrome and related diseases (entinostat.net review).

Mechanism of Action of Acifran

Acifran binds the orthosteric pocket of HM74A/GPR109A and GPR109B, stabilizing the active conformation of each GPCR. Cryo-EM structures demonstrate that Acifran engages distinct residues in HCAR2 and HCAR3, such as F107^3.32 (HCAR3) or L107^3.32 (HCAR2), driving selectivity (Ye et al., 2025). Ligand-receptor interaction is further modulated by pocket size and residue configuration (notably V/L83^2.60, Y/N86^2.63, S/W91^2.48). Upon activation, Acifran triggers intracellular Gi-coupled signaling, leading to inhibition of adenylate cyclase and reduced cyclic AMP (cAMP) levels. This cascade suppresses lipolysis, thereby lowering plasma free fatty acid concentrations and modulating lipid homeostasis. The selectivity profile of Acifran, confirmed by cAMP inhibition assays in HEK-293 cells, enables its use in dissecting receptor-specific effects without notable off-target activity (PrecisionFDA article).

Evidence & Benchmarks

• High-resolution cryo-EM structures of Acifran in complex with HCAR3 (3.18 Å) and HCAR2 (2.72 Å) define the atomic basis for selectivity (Ye et al., 2025).
• Structure-function analysis reveals that Acifran’s π–π interaction with F107^3.32 in HCAR3 underlies its higher affinity for this receptor (Ye et al., 2025).
• cAMP inhibition assays in HEK-293 cells confirm functional agonism and receptor selectivity at nanomolar concentrations (Ye et al., 2025).
• Acifran exhibits solubility below 21.82 mg/ml in ethanol and DMSO, supporting protocol compatibility with standard in vitro assays (APExBIO).
• Purity of ≥98% and off-white solid form ensure high batch-to-batch reproducibility (APExBIO).
• Validated storage parameters (-20°C, blue ice shipment) maintain chemical stability and biological activity (APExBIO).
• Atomic coordinates and density maps deposited at PDB (9JKX, 9JKY) and EMDB (EMD-61573, EMD-61574) support open-access reproducibility (PDB 9JKX).

Applications, Limits & Misconceptions

Acifran’s primary application is in mechanistic and translational studies of lipid metabolism and metabolic disorders. Its selectivity profile enables dissection of HCAR2 vs. HCAR3 signaling. The compound is suitable for research in cell-based assays, structural biology, and pharmacological screening. By leveraging atomic-level data, Acifran allows for structure-guided drug discovery and pathway analysis. For extended discussion of translational potential, see this article, which this review updates by adding recent structural and application benchmarks.

Common Pitfalls or Misconceptions

• Acifran is not a diagnostic or therapeutic agent; it is for scientific research only (APExBIO).
• Long-term storage of Acifran solutions leads to loss of activity; prepare fresh solutions for each experiment (APExBIO).
• The compound’s solubility limit (<21.82 mg/ml) requires careful dissolution for high-concentration applications (APExBIO).
• Not all cell lines express HM74A/GPR109A or GPR109B; confirm receptor presence before functional assays (GPCR.com review).
• HCAR2 and HCAR3 have distinct signaling and tissue distributions; results from one receptor do not generalize to the other (Ye et al., 2025).

Workflow Integration & Parameters

Acifran (SKU B6848) is provided as an off-white solid at ≥98% purity (APExBIO). For optimal performance, store at -20°C and transport with blue ice. Dissolve in ethanol or DMSO to a maximum of 21.82 mg/ml, ensuring immediate use of solutions. For cell-based assays, select concentrations based on receptor expression and assay sensitivity, typically in the 10 nM – 10 μM range. Incorporate negative controls and replicate experiments to ensure data reliability. For a detailed protocol comparison and troubleshooting, see this best-practices guide, which this article extends with additional structural data and workflow recommendations.

Conclusion & Outlook

Acifran is a rigorously validated research compound for dissecting the roles of HM74A/GPR109A and GPR109B in lipid metabolism. Structural and functional studies position Acifran as a reference agonist for GPCR-mediated lipid signaling research. Its high purity, stability, and selectivity support advanced experimental design in metabolic disorder research. Ongoing data deposition and open-access resources, such as PDB and EMDB entries, further enhance reproducibility and transparency (Ye et al., 2025). For ordering and technical documentation, refer to the official Acifran product page from APExBIO.